1. Volume 120, Issue 4, Pages 867-873 (March 2001)
Rofecoxib, a COX-2 inhibitor, does not inhibit human gastric mucosal prostaglandin production 
Nicholas J. Wight, Keith Gottesdiener, Nigel M. Garlick, Clare T. Atherton, Sue Novak, Barry J. Gertz, Nicole A. Calder, J. Cote, P. Wong, Amy Dallob, Chris J. Hawkey 
Gastroenterology 
Volume 120, Issue 4, Pages (March 2001)
DOI: /gast
Copyright © 2001 American Gastroenterological Association Terms and Conditions

2. Fig. 1
Diagram of the scheme used when taking 12 mucosal biopsy specimens from the gastric antrum at the end of each treatment period. Care was taken to ensure that specimens were taken from different sites in each study period.
Gastroenterology  , DOI: ( /gast )
Copyright © 2001 American Gastroenterological Association Terms and Conditions

3. Fig. 2
Gastric mucosal PGE2 synthesis rates (pg · mg−1 · min−1) determined ex vivo after 5-day treatment with rofecoxib/placebo or naproxen/placebo (geometric mean ± between-subject SE). Each subject's gastric PGE2 synthesis value was an average over 12 gastric mucosal biopsy specimens.
Gastroenterology  , DOI: ( /gast )
Copyright © 2001 American Gastroenterological Association Terms and Conditions

4. Fig. 3
The percent change from baseline in LPS-stimulated PGE2 production in whole blood after 5-day treatment with rofecoxib/placebo or naproxen/placebo (geometric mean ± between subject SE).
Gastroenterology  , DOI: ( /gast )
Copyright © 2001 American Gastroenterological Association Terms and Conditions

5. Fig. 4
The percent change from baseline in serum-generated TXB2 in whole blood after 5-day treatment with rofecoxib/placebo or naproxen/placebo (geometric mean ± between-subject SE).
Gastroenterology  , DOI: ( /gast )
Copyright © 2001 American Gastroenterological Association Terms and Conditions